![Cynthia Anderson](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Cynthia Anderson
Keine laufenden Positionen mehr
Vermögen: 8 065 $ am 31.05.2026
Profil
Cynthia L.
Anderson formerly worked at Alnylam Pharmaceuticals, Inc., as Chief Accounting Officer from 2019 to 2023 and Vistagen Therapeutics, Inc., as Chief Financial Officer from 2023 to 2025.
Ms. Anderson received her undergraduate degree from the University of Connecticut and graduate degree from The University of Texas at Dallas.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 16.07.2025 | 12.801 ( 0,03 % ) | 8 065 $ | 31.05.2026 |
Ehemalige bekannte Positionen von Cynthia Anderson
| Unternehmen | Position | Ende |
|---|---|---|
| VISTAGEN THERAPEUTICS, INC. | Finanzdirektor/CFO | 15.09.2025 |
| ALNYLAM PHARMACEUTICALS, INC. | Comptroller/Controller/Auditor | 01.01.2023 |
Ausbildung von Cynthia Anderson
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
15
Beziehungen ersten Grades
4
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 4 |
|---|---|
Alnylam Pharmaceuticals, Inc.
 Alnylam Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapeutics based on RNA interference | Health Technology |
University of Connecticut
 University of Connecticut Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The University of Texas at Dallas
 The University of Texas at Dallas Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
VistaGen Therapeutics, Inc.
 VistaGen Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops central nervous system therapies | Health Technology |
